Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06158828 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
A Phase 1 study of Acute Myeloid Leukemia and AML, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06158828 is a Phase 1 study of Acute Myeloid Leukemia and AML that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 68 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06158828, a Phase 1 study of Acute Myeloid Leukemia and AML, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Busulfan
- DRUG Thiotepa
- DRUG Rabbit Anti thymocyte globulin
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2030-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06158828
The ClinicalTrials.gov registry entry for NCT06158828 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (41% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT06158828 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06158828 about?
NCT06158828 is a clinical study titled "Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML". This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
What is the current status of trial NCT06158828?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2024-05-15. Estimated completion is 2030-05-31.
What conditions does trial NCT06158828 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, AML, AML, Childhood, Acute Myeloid Leukemia, Pediatric.
What interventions are being tested in trial NCT06158828?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Busulfan (DRUG), Thiotepa (DRUG), Rabbit Anti thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT06158828?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06158828 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.